MA31903B1 - Derives de thiazole utilises comme inhibiteur de la pi 3 kinase - Google Patents

Derives de thiazole utilises comme inhibiteur de la pi 3 kinase

Info

Publication number
MA31903B1
MA31903B1 MA32896A MA32896A MA31903B1 MA 31903 B1 MA31903 B1 MA 31903B1 MA 32896 A MA32896 A MA 32896A MA 32896 A MA32896 A MA 32896A MA 31903 B1 MA31903 B1 MA 31903B1
Authority
MA
Morocco
Prior art keywords
kinase
inhibitors
thiazole derivatives
compounds
thiazole
Prior art date
Application number
MA32896A
Other languages
Arabic (ar)
English (en)
Inventor
Giorgio Caravatti
Robin Alec Fairhurst
Pascal Furet
Vito Guagnano
Patricia Imbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31903B1 publication Critical patent/MA31903B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (i) : et leurs sels, dans laquelle les substituants sont tels que définis dans la description, des compositions et l'utilisation des composés dans le traitement de maladies améliorées par l'inhibition de la phosphatidylinositol 3-kinase.
MA32896A 2007-12-20 2010-06-08 Derives de thiazole utilises comme inhibiteur de la pi 3 kinase MA31903B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07150228 2007-12-20
PCT/EP2008/067859 WO2009080694A1 (fr) 2007-12-20 2008-12-18 Dérivés de thiazole utilisés comme inhibiteur de la pi 3 kinase

Publications (1)

Publication Number Publication Date
MA31903B1 true MA31903B1 (fr) 2010-12-01

Family

ID=39273277

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32896A MA31903B1 (fr) 2007-12-20 2010-06-08 Derives de thiazole utilises comme inhibiteur de la pi 3 kinase

Country Status (28)

Country Link
US (1) US8940771B2 (fr)
EP (1) EP2240475B1 (fr)
JP (1) JP2011506560A (fr)
KR (1) KR20100093129A (fr)
CN (1) CN101952282A (fr)
AR (1) AR069798A1 (fr)
AU (1) AU2008340053A1 (fr)
BR (1) BRPI0820722A2 (fr)
CA (1) CA2710122A1 (fr)
CL (1) CL2008003822A1 (fr)
CO (1) CO6321276A2 (fr)
CR (1) CR11491A (fr)
DO (1) DOP2010000183A (fr)
EA (1) EA201000947A1 (fr)
EC (1) ECSP10010271A (fr)
ES (1) ES2437595T3 (fr)
IL (1) IL206286A0 (fr)
MA (1) MA31903B1 (fr)
NI (1) NI201000107A (fr)
PA (1) PA8809001A1 (fr)
PE (1) PE20091523A1 (fr)
SM (1) SMP201000096B (fr)
SV (1) SV2010003598A (fr)
TN (1) TN2010000293A1 (fr)
TW (1) TW200930364A (fr)
UY (1) UY31545A1 (fr)
WO (1) WO2009080694A1 (fr)
ZA (1) ZA201003928B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
EP2183225A1 (fr) 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Pyrimidinediamines substituées par des amines cycliques utilisées en tant qu'inhibiteurs de la pkc
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CA2766853A1 (fr) * 2009-07-02 2011-01-06 Novartis Ag 2-carboxamide cycloamino urees utiles en tant qu'inhibiteurs de la pi3k
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CA2773661A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Derives ethers d'heteroaryles bicycliques
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
EP2582680A1 (fr) 2010-06-17 2013-04-24 Novartis AG Dérivés de 1,3 dihydro-benzoimidazol-2-ylidène-amine à substitution biphényle
CN105412105A (zh) * 2010-11-08 2016-03-23 诺华有限公司 2-甲酰胺环氨基尿素衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的药剂有获得性耐受性的疾病中的应用
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
EP2683722A1 (fr) 2011-03-08 2014-01-15 Novartis AG Composés hétéroaryliques bicycliques de type fluorophényle
EP2763532B1 (fr) 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Inhibiteurs de pi-kinase à activité anti-infectieuse à large spectre
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
CA2865993A1 (fr) * 2012-03-30 2013-10-03 Novartis Ag Composes pour utilisation dans le traitement de neuroblastome, sarcome d'ewing ou un rhabdomyosarcome
KR101761464B1 (ko) 2012-05-23 2017-07-25 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
PT2897644T (pt) * 2012-09-20 2018-10-16 Novartis Ag Associação farmacêutica compreendendo um inibidor de fosfatidilinositol 3-quinase e um inibidor da aromatase
CN103232406B (zh) * 2013-04-26 2015-07-29 北京大学 一种1,3-噻唑衍生物
GB201308278D0 (en) * 2013-05-08 2013-06-12 Imp Innovations Ltd Labelled Carboxylic Acids and Their Uses in Molecular Imaging
AU2016288204B2 (en) * 2015-06-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
CN105294546B (zh) * 2015-10-29 2017-12-08 天津市斯芬克司药物研发有限公司 一种吡啶化合物及其制备方法
WO2017147526A1 (fr) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs de la pi-kinase à activité anti-infectieuse
CN109111439B (zh) * 2017-06-26 2020-09-18 深圳市塔吉瑞生物医药有限公司 一种酰胺类化合物及包含该化合物的组合物及其用途
AU2019355574A1 (en) * 2018-10-05 2021-05-06 Sloan-Kettering Institute For Cancer Research PI3K inhibitors and uses thereof
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
TW202140437A (zh) * 2020-01-07 2021-11-01 美商達薩瑪治療公司 Sarm1抑制劑
WO2024089272A1 (fr) * 2022-10-28 2024-05-02 Institut National De La Sante Et De La Recherche Medicale Nouveaux inhibiteurs de la phosphatidylinositol 3-kinase

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3427115A1 (de) * 1984-07-23 1986-03-27 Dedo Weigert Film GmbH, 8000 München Ueberwachungsgeraet
DE3703435A1 (de) 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
WO1989007105A1 (fr) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine
AU615544B2 (en) 1988-04-15 1991-10-03 Taiho Pharmaceutical Co., Ltd. Carbamoyl-2-pyrrolidinone compounds
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
CA2123096A1 (fr) 1991-11-08 1993-05-13 Beat J. Knusel Compositions contenant des composes k-252 pour la potentialisation de l'activite neurotrophine
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
CA2123895A1 (fr) 1992-09-21 1994-03-31 Tatsuya Tamaoki Agent pour le traitement de la thrombocytopenie
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP1110953B1 (fr) 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (fr) 1995-08-11 1997-02-27 Yale University Synthese d'indolocarbazols glycosyles
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
EP0865440B1 (fr) 1995-12-08 2002-04-03 Janssen Pharmaceutica N.V. Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
AU738592C (en) 1996-08-02 2002-07-25 Lorus Therapeutics Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
WO1998027108A2 (fr) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amide
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
EP1017394B1 (fr) 1997-07-12 2005-12-07 Cancer Research Technology Limited Derives de purine inhibant la kinase dependant de la cycline
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
CA2332325A1 (fr) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Aminothiazole a substituant carbone, inhibiteurs de kinases dependantes de cycline
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US6806266B1 (en) 1999-07-13 2004-10-19 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
KR20020027635A (ko) 1999-09-10 2002-04-13 폴락 돈나 엘. 티로신 키나제 억제제
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
CA2399358C (fr) 2000-02-15 2006-03-21 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
CA2401748A1 (fr) 2000-03-29 2001-10-04 Cyclacel Limited 4-heteroaryle-pyrimidines substituees en 2 et leur utilisation dans le traitement de troubles proliferants
PT1274718E (pt) 2000-04-12 2007-01-31 Genaera Corp Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido
JP4102185B2 (ja) 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1256578B1 (fr) 2001-05-11 2006-01-11 Pfizer Products Inc. Dérivés de thiazole et leur utilisation comme inhibiteurs de cdk
EP1404689A1 (fr) 2001-07-02 2004-04-07 Debiopharm S.A. Substance active a base d'oxaliplatine presentant une faible teneur en acide oxalique
US7232838B2 (en) 2001-08-13 2007-06-19 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
MXPA04002914A (es) 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
WO2003077902A1 (fr) 2002-02-19 2003-09-25 Xenoport, Inc. Procede de synthese de promedicaments a partir de derives de 1-acyl-alkyl et compositions correspondantes
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
CA2480638C (fr) 2002-03-29 2013-02-12 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf
US6900342B2 (en) 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
DE60332475D1 (de) 2002-10-30 2010-06-17 Vertex Pharma Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
EP1567487A4 (fr) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
EP1587473A4 (fr) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic Thiosemicarbazones antiviraux et immunostimulants
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
PL1709019T3 (pl) * 2004-01-12 2007-10-31 Merck Serono Sa Tiazolowe pochodne i ich zastosowanie
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
JP5203937B2 (ja) 2005-05-24 2013-06-05 メルク セローノ ソシエテ アノニム チアゾール誘導体及びその使用
WO2006125805A1 (fr) 2005-05-24 2006-11-30 Laboratoires Serono S.A. Derives thiazole et utilisation
US7655446B2 (en) 2005-06-28 2010-02-02 Vertex Pharmaceuticals Incorporated Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007070600A2 (fr) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. Composés antiviraux n-(noyau aromatique à 5 chaînons) amido
GB0525671D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2007082956A1 (fr) 2006-01-23 2007-07-26 Laboratoires Serono S.A. Dérivés de thiazole et leur utilisation
GB0610243D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
WO2008064218A2 (fr) 2006-11-21 2008-05-29 Smithkline Beecham Corporation Composés amido antiviraux
WO2008124000A2 (fr) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes
AU2008257559B2 (en) 2007-05-25 2013-10-10 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor)
US20090004140A1 (en) 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
WO2009012482A2 (fr) 2007-07-19 2009-01-22 H.Lundbeck A/S Amides heterocycliques a 5 chainons et composes associes
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Also Published As

Publication number Publication date
ECSP10010271A (es) 2010-07-30
CO6321276A2 (es) 2011-09-20
WO2009080694A1 (fr) 2009-07-02
US8940771B2 (en) 2015-01-27
CR11491A (es) 2010-08-05
CN101952282A (zh) 2011-01-19
SMP201000096B (it) 2011-09-09
EP2240475B1 (fr) 2013-09-25
NI201000107A (es) 2011-03-15
EA201000947A1 (ru) 2011-02-28
KR20100093129A (ko) 2010-08-24
US20090163469A1 (en) 2009-06-25
ES2437595T3 (es) 2014-01-13
TW200930364A (en) 2009-07-16
AU2008340053A1 (en) 2009-07-02
CA2710122A1 (fr) 2009-07-02
IL206286A0 (en) 2010-12-30
BRPI0820722A2 (pt) 2015-06-16
UY31545A1 (es) 2009-08-03
SMAP201000096A (it) 2010-09-10
JP2011506560A (ja) 2011-03-03
ZA201003928B (en) 2011-04-28
TN2010000293A1 (en) 2011-11-11
CL2008003822A1 (es) 2009-06-26
EP2240475A1 (fr) 2010-10-20
AR069798A1 (es) 2010-02-17
PA8809001A1 (es) 2009-07-23
PE20091523A1 (es) 2009-10-29
SV2010003598A (es) 2011-03-23
DOP2010000183A (es) 2010-07-31

Similar Documents

Publication Publication Date Title
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
SMP201100019B (it) Composti organici
EA200802329A1 (ru) Производные триазола ii
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA201000098A1 (ru) Производные хиназолинамида
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
MA35285B1 (fr) Indazoles
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
GEP20156250B (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
EA201300052A1 (ru) [1,8]нафтиридиновые производные
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA31296B1 (fr) Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek